Abstract
The herpes simplex virus (HSV) amplicon vector is a versatile plasmid-based gene delivery vehicle with a large transgene capacity (up to 150 kb) and the ability to infect a broad range of cell types. The vector system was originally developed by Frenkel and her colleagues in 1980. Ever since, a great deal of effort by various investigators has been directed at minimizing the toxicity associated with the inevitable contamination by helper virus. In 1996, Fraefel and his colleagues successfully devised a cosmid-based packaging system that was free of contamination by helper virus (socalled helper virus-free packaging), which utilized as helper a set of 5 overlapping cosmid clones that covered the entire HSV genome, which lacked the DNA packaging/cleavage signals. With the helper virus-free system, broader applications of the vector became possible. Cloning of the entire HSV genome in bacteria artificial chromosome (BAC) plasmids enabled stable maintenance and propagation of the helper HSV genome in bacteria. It also allowed for the development of BAC-based helper virus-free packaging systems. In this article, we review various versions of DNA-based methods to prepare HSV amplicon vectors free of helper virus contamination. We also examine recent advances in vector design, including methods of vector construction, hybrid amplicon vectors, and the infectious BAC system. Future directions in improving packaging systems and vector designs are discussed.
Keywords: Herpes simplex virus, bacterial artificial chromosome (BAC), HSV amplicon, packaging system, hybrid amplicon, infectious bacterial artificial chromosome (iBAC)
Current Gene Therapy
Title: DNA-Based Methods to Prepare Helper Virus-Free Herpes Amplicon Vectors and Versatile Design of Amplicon Vector Plasmids
Volume: 6 Issue: 3
Author(s): Kazue Kasai and Yoshinaga Saeki
Affiliation:
Keywords: Herpes simplex virus, bacterial artificial chromosome (BAC), HSV amplicon, packaging system, hybrid amplicon, infectious bacterial artificial chromosome (iBAC)
Abstract: The herpes simplex virus (HSV) amplicon vector is a versatile plasmid-based gene delivery vehicle with a large transgene capacity (up to 150 kb) and the ability to infect a broad range of cell types. The vector system was originally developed by Frenkel and her colleagues in 1980. Ever since, a great deal of effort by various investigators has been directed at minimizing the toxicity associated with the inevitable contamination by helper virus. In 1996, Fraefel and his colleagues successfully devised a cosmid-based packaging system that was free of contamination by helper virus (socalled helper virus-free packaging), which utilized as helper a set of 5 overlapping cosmid clones that covered the entire HSV genome, which lacked the DNA packaging/cleavage signals. With the helper virus-free system, broader applications of the vector became possible. Cloning of the entire HSV genome in bacteria artificial chromosome (BAC) plasmids enabled stable maintenance and propagation of the helper HSV genome in bacteria. It also allowed for the development of BAC-based helper virus-free packaging systems. In this article, we review various versions of DNA-based methods to prepare HSV amplicon vectors free of helper virus contamination. We also examine recent advances in vector design, including methods of vector construction, hybrid amplicon vectors, and the infectious BAC system. Future directions in improving packaging systems and vector designs are discussed.
Export Options
About this article
Cite this article as:
Kasai Kazue and Saeki Yoshinaga, DNA-Based Methods to Prepare Helper Virus-Free Herpes Amplicon Vectors and Versatile Design of Amplicon Vector Plasmids, Current Gene Therapy 2006; 6 (3) . https://dx.doi.org/10.2174/156652306777592081
DOI https://dx.doi.org/10.2174/156652306777592081 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Melatonin Signaling in Health and Disease
Melatonin regulates a multitude of physiological functions, including circadian rhythms, acting as a scavenger of free radicals, an anti-inflammatory agent, a modulator of mitochondrial homeostasis, an antioxidant, and an enhancer of nitric oxide bioavailability. AANAT is the rate-limiting enzyme responsible for converting serotonin to NAS, which is further converted to ...read more
The now and future of gene transfer technologies
Gene and cell therapies rely on a gene delivery system which is safe and effective. Both viral and non-viral vector systems are available with specific pros and cons. The choice of a vector system is largely dependent on the application which is a balance between target tissue/disease and safety, efficacy ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Drug Resistance and Apoptosis in Cancer Treatment: Development of New Apoptosis-Inducing Agents Active in Drug Resistant Malignancies
Current Medicinal Chemistry - Anti-Cancer Agents Potential Anticancer Effect of Carvacrol Codrugs on Human Glioblastoma Cells
Current Drug Delivery Natural Bio-Drugs as Matrix Metalloproteinase Inhibitors: New Perspectives on the Horizon?
Recent Patents on Anti-Cancer Drug Discovery Phagoptosis - Cell Death By Phagocytosis - Plays Central Roles in Physiology, Host Defense and Pathology
Current Molecular Medicine Modern drug delivery systems for targeting the posterior segment of the eye
Current Pharmaceutical Design DNA Demethylation: Where Genetics Meets Epigenetics
Current Pharmaceutical Design Targeted Tumor Diagnosis and Therapy with Peptide Hormones as Radiopharmaceuticals
Anti-Cancer Agents in Medicinal Chemistry Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges
Current Pharmaceutical Biotechnology MicroRNAs as Cancer Biomarkers
MicroRNA Editorial [Hot topic: Targeting Nitric Oxide for Tumor Therapy (Executive Editor: Antonio Contestabile)]
Current Pharmaceutical Design Rock1 & 2 Perform Overlapping and Unique Roles in Angiogenesis and Angiosarcoma Tumor Progression
Current Molecular Medicine Melanoma Differentiation Associated Gene-7 (mda-7)/ Interleukin-24 (IL-24), mda-7/IL-24: Current Perspectives on a Unique Member of the IL-10 Family of Cytokines
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prediction and Early Evaluation of Anticancer Therapy Response: From Imaging of Drug Efflux Pumps to Targeted Therapy Response
Current Medicinal Chemistry Radiolabeled Nucleoside Analogues for PET Imaging of HSV1-tk Gene Expression
Current Topics in Medicinal Chemistry Astrocyte Signaling and Multiple Sclerosis
Current Signal Transduction Therapy Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design Remodelling of the Ca2+ Toolkit in Tumor Endothelium as a Crucial Responsible for the Resistance to Anticancer Therapies
Current Signal Transduction Therapy A Novel Polyarginine Containing Smac Peptide Conjugate that Mediates Cell Death in Tumor and Healthy Cells
Medicinal Chemistry Preface
Current Pharmaceutical Design Potential Cancer Gene Therapy by Baculoviral Transduction
Current Gene Therapy